Neurotech International

Neurotech International Debt

Debt of Neurotech International (NTI.AX) as of Nov 15, 2026.

Debt

0.00AUD

Last updated:

In 2025, Neurotech International's total debt was 0.00 AUD, a % change from the 0.00 AUD total debt recorded in the previous year.

The Neurotech International Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
29,788.00 AUD
Jan 1, 2019
126,074.00 AUD
Jan 1, 2020
54,201.00 AUD
Jan 1, 2021
0.00 AUD
Jan 1, 2022
0.00 AUD
Jan 1, 2023
0.00 AUD
Jan 1, 2024
0.00 AUD
Jan 1, 2025
0.00 AUD
The Neurotech International Debt history
YEARDebtYoY
0.00AUD—
0.00AUD—
0.00AUD—
0.00AUD—
0.00AUD-100.00%
54,201.00AUD-57.01%
126,074.00AUD+323.24%
29,788.00AUD-92.05%
374,806.00AUD-2.80%
385,609.00AUD-22.54%
497,831.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Neurotech International Stock analysis

What does Neurotech International do? Neurotech International Ltd. generates revenue through the development and commercialization of medical devices and solutions, primarily targeting pediatric neurological disorders. The company's key product, Mente Autism, is a portable EEG headband that uses closed-loop neurofeedback to assist children with autism spectrum disorder (ASD) by improving relaxation and engagement. Clinical studies assess the neuro-protective and anti-inflammatory effects of its NTI/Dolce cannabis strains, which are part of its development program NTI164 that completed a Phase I/II trial for ASD treatment. The firm focuses on commercializing these neurological solutions for pediatric use in home therapy settings. The company's primary customers are families and healthcare providers managing children with autism spectrum disorder (ASD). Mente Autism is marketed as a home therapy device to increase engagement and reduce anxiety in autistic children with elevated delta-band brain activity. Neurotech International Ltd. leverages its clinical trial results to support the commercialization of Mente Autism and its NTI/Dolce cannabis strains, which are positioned as therapeutic solutions for neurological conditions. The firm's revenue streams are derived from the sale of Mente Autism devices and the potential future commercialization of its NTI/Dolce cannabis-based products. Neurotech International Ltd. operates within the medical device sector, emphasizing pediatric neurological solutions. Its products, including Mente Autism and the NTI/Dolce cannabis strains, are developed through clinical studies to address specific neurological disorders. The company's focus on home-based therapy for ASD patients differentiates its offerings in the market, targeting a niche segment of families seeking non-invasive, accessible treatments for children with autism. Neurotech International is one of the most popular companies on Eulerpool.

Debt Details

Understanding Neurotech International's Debt Structure

Neurotech International's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Neurotech International's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Neurotech International’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Neurotech International’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Neurotech International stock

On Eulerpool you can find the complete historical development of Debt Neurotech International since 2006 – with annual values, charts, and detailed analysis.

Debt's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Neurotech International historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Neurotech International

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Neurotech International